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Objectwes. The hypothesis was that cardiac surgery for symp- 
tomatic caecinoid heart disease in conjunction with adjunctive 
therapy could improve the long-term outlook of patients with 
carcinoid heart disease. 
Background. Patients with car&aid heart disease have a 
dismal prognosis; most die of progressive right heart failure 
within 1 year after onset of symptoms. Improved therapies for the 
systemic manifestations of Ike carcinoid syndrome have resulted 
in symptomatic improvement and prolonged survival in patients 
without heart disease. 
Metho&. Twenty-six patients witb symptomatic carcinoid heart 
disease underwent valvular surgery. Preoperative clinical, labora- 
tory, Doppler echocardiographic and hemodynamic factors were 
evaluated. The survival of the surgical group was compared with 
that of a control group of 40 medically treated patients. 
Results. There were nine perioperative deaths (35%), primarily 
from postoperative bleeding and right ventricular failure. Of the 
17 surgical survivors, 8 were alive at a mean of 28 months of 
The malignant carcinoid syndrome consists of vasomotor 
changes, gastrointestinal hypermotility, bronchospasm and 
right sided valvular heart disease. It portends a poor prognosis, 
par?icularly in patients with progressive cardiac involvement. 
Without treatment, the median duration of survival with the 
malignant carcinoid syndrome is 38 months from the onset of 
systemic symptoms. With clinica! evidence of carcinoid heart 
disease, the median duration of survival is only 11 months (i). 
Because of this poor prognosis, patients with carcinoid heart 
disease had previously been treated only with medications for 
relief of symptoms of heart failure and experienced a contin- 
ued high mortality rate from progressive right heart failure. 
During the past decade, several new treatments have 
emergeci for patients with the malignant carcinoid syndrome. 
Somatostatin is a ubiquitous hormone that inhibits tile rzlease 
of numerous peptides, such as growth hormone, insulin, glu- 
cagon and gut peptides (2). It was initiaiiy reported to be 
effective in blocking the carcinoid flush induced by pentagas- 
trin as well as in controlling other symptoms associated with 
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follow-up. The postoperative functional class of the eight surviving 
patients was substantially improved. Late deaths were primarily 
due to hepatic dysfimction caused by metastatic disease. The only 
predictor of operative mortality (p = 0.03) was low voltage on 
preoperative electrocardiography (limb lead voltage ~5 mm). 
Predictors of late survival included a lower preoperative soma- 
tn$atin requirement and a Icier preoprrative urinary Mydroxy- 
indoleacetic acid level. Tbere was a trend toward increased 
survival for the surgical group compared with the control group. 
Coahsions. Because new therapies have improved survival in 
patients with the malignant carcinoid syndrome, cardiac involve- 
ment has become a major cause of morbidity and mortality. Valve 
surgery is the duly definitive treatment. Although cardiac surgery 
carries a high perioperative mortality, marked symptomatic im- 
provement occurs in survivors. Surgical intervention Ebould 
therefore be considered when cardiac symptoms become severe. 
(J Am Coil Cardiol1995;25:410-6) 
the carcinoid syndrome (3,4). However, the early use of 
somatostatin had limited therapeutic application because of 
the short half-life of the native somatostatin compound. The 
somatostatin analog sandostatin (SMS 201..995) was developed 
and has subsequently proved to be more potent and longe: 
acting in its inhibitory effects than naturally occurring soma- 
tostatin (5). This therapeutic agent hss resulted in marked 
symptomatic improvement and improved survival of patients 
with the malignant carcinoid syndrome (6-8). Hepatic deart- 
erialization by ligation or occlusion has also been extremely 
effective in relieving the symptoms of the malignant carcinoid 
syndrome by inducing rapid tumor shrinkage in patients who 
have carcinoid tumors with hepatic metastases (9-12). 
Despite the alleviation of systemic symptoms by these 
measures, patieuts in whom carcinoid cardiac involvement had 
already developed contini,&d to experience progressive symp- 
toms of right-sided heart iailure and mortality from cardiac 
causes. It was our hrpothesis that if the severe hemodynamic 
consequences of the valvular abnormalities of carcinoid heart 
disease could be corrected surgically, in conjunction with 
control of the systemic manifestations of the malignant carci- 
noid syndrome by the newer therapeutic methods, the long- 
term outlook for these patients could be substantially im- 
proved. Between 1985 and 1992, 26 patients with advanced 
carcinoid heart disease underwent valvular surgery in an 
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Table 1. Hemodymic Data in 26 Patients With C arcinoid IHeart Diseare 
-_~--. ..__I_ 
rchocardiography 
TR velocity (mm Hq) 
Peak pulmo!wy velocity (mh) 
TV mean gradient (mm Hg) 
LVEF (57,) 
LVEF <55% 
Reduced RV FjaWliC func!ion 
Pericardial effusion 
Catheterization 
PAP (mm Hg) 
RVEDP (mm Hg) 
RQJ (mm W 
CO (Urnin) 
Dye method 
Fick method 
Range Nu. of Patients 
2.4 i U.6 1.25-3.6 2.; 
2.0 t 0.9 1.6-3.5 21 
4.5 i 1.1 W-S.0 L3 
60 :: 9 42-75 25 
3Qb(llQ) 
17m (46’:) 
13126 (SOS:) 
27 + 6 14-36 17 
1824 14-29 14 
29 z 9 13-40 16 
3.9 t 1.2 2.1-6.5 13 
4.u 1.1 2.94.; - 6 
Data presented are mean value L SD or number (5%) of patients. CO = cardiac output; LVEF = !eft ventricular 
ejection fraction; PAP = mean pulmonary artery pressure; RAP = r&b? atrial pressure: RV = right ventricle; RVEDP = 
right ventricular end-diastolic pressure; TR = tricuspid regurgitation: TV = tricuspid valve. 
attempt to improve symptoms and longevity. We report the 
surgical outcome and portoperative survival of these patients. 
Methods 
Selection of patients. Fifty-eight percent of patients with 
the malignant carcinoid syndrol I who are referred to our 
echocardiographic laboratory have evidence of carcinoid heart 
disease by echocardiography (13). Because of the known poor 
prognosis of patients with symptomatic carcinoid heart disease, 
a decision strategy was made to offer valve surgery to patients 
who met the following three criteria: 1) systemic carcinoid 
symptoms well controlled by somatostatin or hepatic dearteri- 
alization, 2) severe symptoms of right heart failure caused by 
carcinoid valvular involvement, and 3) no other concc;::nt 
major medical illnesses. Twenty-six patients met these criteria 
and were referred for valvular surgery (16 men, 10 women; 
mean age 54 years, range 25 to 72). Twenty-five patient,; had 
primary disease in the intestine with hepatic mctastases. The 
remaining patient had primary ovarian car inoid tumor with- 
out hepatic metastares (because of the systemic venous drain- 
age of the ovary) , .4). The mean interval from the diagnosis of 
carcinoid syndrome to operation was 42 months. As a means to 
assess the association between surgical treatment and survival 
outcome, the 26 patients who underwent operation were 
studied in the context of 66 total patients at the Mayo Clinic 
who had carcinoid heart disease and New York Heart Associ- 
ation class III or XV symptoms of heart failure. Thus, 40 
patients who did not undergo operation served as a historical 
control group. I 
Clinical and laboratory findings. The preoperative evalu- 
ation included a complete history and physical examination, 
electrocardiography, chest radiography and determination of 
urinary Shydroxyindoleacetic acid levels in all patients. The 
urinary 5-hydroxyindoleacetic acid test is remarkably specific 
and reproducible and provides a reliable biologic marker for 
the assessment of tumor activity and treatment intervention 
(15). The mean preoperative 5-hydroxyindoleacetic acid value 
for the 26 patients was 197 mg/24 h (median 172, range 2.1 to 
416, normal 0 to 6.0). The patient with primary ovarian 
carcinoid tumor without metastatic hepatic disease had the 
normal 5-hydro.xyindoleacetic acid level (2.1 mg124 h). 
The preoperative somatostatin dose and duration of ther- 
apy were determined. The usual initial dosage is 150 kg 
administered subcutaneously three times daily. Increased dos- 
ages were administered for breakthrough qmptoms or for the 
development of tachyphylaxis. The mean somatostatin dose at 
the time of cardiac operation was 952 r.l.glday (range 450 to 
3,00(?). Three patients were not receiving somatostatin at the 
time of operation. 
Physical examinati,on demonstrated jugular venous disten- 
tion, prominent v waves (caused by tricuspid regurgitation), 
variable a waves (caused by tricuspid stenosis), a right precor- 
dial lift (caused by right ventricular enlargement) and murmurs 
of tricuspid and pulmonary involvement in all patients. 
The electrocardiogram (ECG) in patients with carcinoid 
heart disease demonstrated one or more of the following: low 
voltage in 22 (85%), right atria1 enlargement in 9 (35%), right 
ventricular enlargement in 4 (15%) and right bundle-branch 
block in 11 (42%). The chest radiographic findings included 
cardiomegaly in 18 (69%), primarily from right-sided cardiac 
chamber and pulmonary artery enlargement; additional find- 
ings included pleural effusions in 15 (58%) and pleural thick- 
ening in 9 (35%). 
Comprehensive preoperative echocardiographic-Doppler 
examination and cardiac catheterization were performed in 25 
and 17 patients, respectively (Table 1). Of the nine patients 
who did not have preoperative cardiac catheterization, four 
had hemodynamic PI :ssure assessment at the time of opera- 
tion. All patients referred for cardiac operation had severe 
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Figure 1. Number and type of cardiac procedures in 26 patients 
with carcinoid heart disease. AVR = aortic valve replacement; 
CABG = coronary artery bypass graft surgery; MVR = mitral 
valve replacement; PFO = patent foramen ovale; PV = pulmo- 
nary valve procedure; WR = tricuspid vake replacement. 
TVR PV MWI AVR PFO CABG Em or 
closure myccardiial 
Procedure reseciion 
tricuspid regurgitation determined by echocardiography or 
catheterization or both. Severe elevation of right atria1 pres- 
sure with a predominant large CV wave was present in all 
patients undergoing catheterization. The mean anterograde 
diastolic tricuspid gradient ranged from 2.0 to 8.0 mm Hg 
(mean 4.5 t 1.7, n = 23). Pulmonary regurgitation was consid- 
ered moderate or greater in 18 (72%) of the 25 patients who had 
preoperative echocardiography. Of 21 patients who had a puhno- 
nary valve gradient measured, all had a systolic gradient 
~10 mm Hg, indicating intrinsic puhnonic stenosis. In addition to 
@h&sided valvular heart disease, three patients had significant 
left-sided valvular disease that required surgical intervention 
(only one of these patients had a patent foramen ovale, and none 
had priiary endobronchial carcinoid). Five patients were identi- 
fied as having a patent foramen ovale by echocardiography or at 
operation. Coronary angiography was performed in 17 (65%) of 
26 patients, and 2 patients had coronary artery stenosees 250% 
diameter narrowing. 
Surgical management. The surgical procedures performed 
are shown in Figure 1. All patients had tricuspid valve replace- 
ment for the severe tricuspid regurgitation (20 mechanical and 
6 bioprosthetic). A pulmonary valve procedure was performed 
in 24 of the 26 patients for relief of the right ventricular outflow 
obstruction: valvectomy in 20 and a pulmonary valve replace- 
ment in 4 (3 homograft, 1 bioprosthetic). The pulmonary 
annulus was enlarged with a pericardial patch in 13 patients. 
One patient underwent mitral and aortic valve replacement 
and closure of a patent foramen ovale in conjunction with 
pulmonary and tricuspid valve procedures. Two patients had 
mitral valve replacement, and four underwent closure of a 
patent forarnen ovale. One patient had coronary artery bypass 
graft surgery performed at the time of the valvular procedure. 
Carcinoid endocardial plaques or intramyocardial carcinoid 
metastases were removed at the time of valvular surgery in five 
patients. One patient required a late pericardiectomy for 
recurrent pericardial etlirsions caused by carcinoid pericardial 
involvement. 
Meticulous anesthetic care was instituted during the oper- 
dtive management of patients with car&lord ireart disease to 
prevent a life-threatening carcinoid crisis (16) or to institute 
early therapy should a crisis occur intraoper:&ively. 
Statistical analysis. Clinical, echocardiographic and car- 
diac catheterization variables were compared between the 
patients who died and those who survived. Mean values k SD 
were calculated for continuous variables and evaluated for 
statistical significance by a two-sample t test. Absolute and 
relative frequencies were measured for discrete variables and 
evaluated with the Fisher exact test. A p value 10.05 was 
considered to indicate statistical significance. 
Survival curves were estimated with the Kaplan-Meier 
approach. Survival postoperatively was estimated in the surgi- 
cal group. Survival in the entire group of 66 patients with 
functional class I!I or worse symptoms during medical therapy 
was estimated from the onset of functional class III symptoms, 
with the surgical patients censored at the time of operation. 
These two survival curves may not be directly comparable 
because the starting time is operation in one case and the onset 
of severe symptoms in the other. As a means to account for 
this, a time-dependent Cox proportional hazards model was fit 
on the entire group, with surgical treatment as a time- 
dependent covariant and onset of functional class III symp- 
toms as the starting time. This analysis was further adjusted for 
age and gender. 
Results 
Surgical outcome. The outcome of valvular surgery for the 
26 patients with carcinoid heart disease is demonstrated in 
Figure 2. There were nine (35%) perioperative deaths (death 
within 30 days of operation or during the same hospital stay). 
Four of these deaths were attributed to cardiovascular causes, 
including postoperative arrhythmic death in one patient, acute 
right ventricular failure in a patient whose stenotic pulmonary 
valve was not removed and progressive hemodynamic deteri- 
oration from right ventricular failure in two patients. Of the 
four perioperative cardiovascular deaths, one patient was in 
functional class IV, two were in functional class III, and one 
was in functional class II preoperatively. The preoperative 
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26 patients with carcinoid heart disease 
Valvolar surgery 
1 
_ll_~_ 9 perioperative deaths 
4 cardiovascular 
3 bleeding 
2 multisystem failure 
Postop 
17 survivors + 9 late deaths 
I 5 21 hepalic n urologic blee in  lmknawn
8 alive and well 
(mean 28 mo follow-up) 
Figure 2. Outcome of valve surgery for 26 patients with carcinoid 
heart disease. 
tunctional class of patients who died perioperatively of cardio- 
vascular causes was not substantially different from the iunc- 
tional class in the rest of the patients. In addition, the 
perioperative deaths were equally distributed over the g-year 
period examined. 
Three perioperative deaths were due to uncontrollable 
bleeding. These patients were 64, 67 and 70 years old; mean 
age of all other patients was 54 years. Significant perioperative 
hemorrhage requiring blood transfusion of ~10 U occurred in 
six patients, the majority of whom had pleura! and pericardial 
plaques (deposits of fibrotic material) present at operation. 
The number of units of blood transfused dming operation 
ranged from 2 to 36 U (mean 9.4 2 8). The remaining two late 
deaths that occurred in the hospital were due to multisystem 
failure. One of these deaths occurred in the youngest patient 
(age 25 years), who had extensive pleural fibrosis and died of 
respiratory failure following lung entrapment. This death 
reemphasizes that patients with extensive pleural or per&dial 
plaque at operation have an increased incidence of periopera- 
tive death (primarily from bleeding) and late death (from lung 
entrapment or restrictive cardiac hemodynamic variables). 
Of the 17 surgical survivors, 8 were alive at a mean of 28 
months of follow-up (range 4 months to 5.2 years), with 
follow-up complete through April 1993. There were nine late 
deaths at a mean of 19 months postoperatively (Fig. 2). The 
majority (five) were due to hepatic dysfunction from metastatic 
disease. There was one late death from ‘viceding, which 
occurred after decortication for lung entrapment caused by 
proliferative pleural thickening. There was one neurologic 
death, and two deaths were of unknown causes. The mean time 
to late death was 19 months postoperatively (range 1 month to 
4.3 years). 
The preoperative and postoperative functional classes of 
the eight patients who were alive at fo!!ow-up are shown in 
Figure 3. The findings show significant symptomatic improve- 
ment in most patients who survive valwlar surgery for symp 
tomatic carcinoid heart disease. 
PredIctsns of survival. The single statistical predictor of 
operative mortality (n = 9 patients) was low voltage (limb lead 
voltage 15 mm) on the preoperative ECG (5.8 ? 1.9 mm 
Figure 3. Preoperative and postoperative New York Heart Assucia- 
tion functional class uf eight patients with cdrcinoid heart disease 
[n = Y] and 7.6 + 1.Y mm [n = 171, p = 0.03). Predictors of late 
survival (n = 8) included a lower preoperative somatostatin 
requirement (525 t 444 ~g [n = 61 and 1,142 f 648 ,ug [n = 
171, p = 0.04) and a iower preoperative 5hydroxyindoIeac& 
acid level (133 -t 97 mg/24 h [n = 81 and 210 -t 79 n@24 h ]n = 
181, p = 0.04). There were no other clinical, echocardiographic 
or catheter-based hemodynamic variabirs associated with a 
higher operative or late mortality rate. The 5k and function ot 
either the left or the right ventricle as assessed by hvo- 
dimensional echocardiography did not predict survival. 
Postoperative survival. Survival after opetation is shown in 
Figure 4. Survival at 2 years was estimated to be 400% (Y5% 
confidence interval [CIJ 0.25 to 0.65). In the entire group, 
survival with medical therapy after onset of functional class III 
symptoms is shown in Figure 4. Survival at 2 years was 8% 
(95% CI interval 0.02 to 0.28). When a time-dependent model 
was fit with operation as the time-dependent covariant, oper- 
ation was associated (p = 0.20 INS]) with a reduced hazard of 
mortality. The hazard ratio wa.s estimated at 0.64 (95% CI 0.32 
to 1.29). There was evidence that the hazard ratio was not 
constant over time, namely, that operation was associated with 
a higher risk early (from perioperative mortahty) but that the 
Figure 4. Actuarial survivaS curves of medically (narrow line) and 
surgically (bold line) managed patirnts with carcinoid heart disease 
(p = 0.20). 
o! I 
0 1 2 3 4 5 
Years 
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relative hazard “flipped>’ a! -6 months, alter which operation 
was associated with a lower hazard. When this analysis was 
adjusted for age and gender, the E imated reiative hazard for 
operation was 0.71 (9.5% CI 0.35 . “3). 
Discussion 
This study documents the results of the strategy to perform 
a cardiac operation for correction of the severe hemodynamic 
consequences of carcinoid heart disease. Even when the pro- 
cedure is done by experienced surgeons, the perioperative 
mortality rate is high. In addition, the short-term postoperative 
mortality continues to be high, primarily because of metastatic 
hepatic disease. Nonetheless, our operative survivors uni- 
formly experienced marked symptomatic improvement at a 
mean follow-up of >2 years. In comparison, the patients with 
severely symptomatic carcinoid heart disease managed without 
surgery underwent progressive hemodynamic deterioration 
and demonstrated a tendency toward reduced survival (Fig. 4). 
Patients with carcinoid heart disease most commonly 
present with features of ihe malignant carcinoid syndrome 
(flushing, diarrhea and breathlessness) in addition to the 
symptoms of right-sided heart failure (hepatomegaly, edema, 
ascites, fatigue and low cardiac output). Rarely, patients 
present with symptomatic left-sided valvular lesions, restrictive 
cardiomyopathy (17), pericardial elision (18), or cyanosis 
(19). The pa:hoiogic characteristics of carcinoid heart disease 
include di@se collections of thick, pearly-white plaque, which 
are composed of smooth muscle ccl!s called “myofibroblasts” 
(20). These plaques are deposited on the endocardial surface 
of the valve cusps on the right side of the heart, resulting in the 
characteristic pathologic and echocardiographic features, 
which include thickening and immobility of the tricuspid and 
pulmonary valve leaflets (13,21). Left-sided valvular involve- 
ment is rare and results from an intracardiac right-to-left shunt 
or a carcinoid endobronchial tumor (13,21). 
Because of the previously described dismal outlook for this 
patient population (l), cardiac surgical intervention until re- 
cently was not considered an option. The advent of newer 
therapeutic methods (somatostatin, hepatic dearterialization) 
for the malignant carcinoid syndrome has resulted in improve- 
ment of the systemic carcinoid symptoms and in survival (6). 
However, despite somatostatin therapy patients with vaivuiar 
involvement continued to experience symptoms of right heart 
failure and substantial cardiac mortality. The improvement in 
noncardiac symptoms and survival with somatostatin therapy 
as well as reported benefit from isolated case reports or series 
of valvular surgery (22-28) led us to pursue a more aggressive 
management of carcinoid heart disease with surgical interven- 
tion. 
Present study. The current series demonstrated several 
important points. First, the need for relief of pulmonary valve 
obstruction was reemphasized by the patient who died of acute 
right ventricular failure when the stenotic pulmonary valve was 
not removed at the time of tricuspid valve replacement. 
Significant obstruction to right ventricular outflow may be 
underestimated because of low pulmonic transvaivuiar gradi- 
ents as a result of the coexistent severe tricuspid regurgitation 
and low cardiac output. We now recommend pulmonary 
valvectomy or pulmonary valve replacement for patients with a 
transpulmonic gradient of >lO mm Hg. Pulmonary valve 
replacement increases the complexity of the operation but 
prevents the late complication of right ventricular failure from 
chronic pulmonary regurgitation after vaivectomy. The best 
surgical approach to the pulmonary valve-valvectomy and 
outflow tract enlargement versus valve replacement-remains 
uncertain, although we would suggest pulmonary valve re- 
placement in patients with elevated left-sided pressures. 
Second, a significant proportion of patients in this series 
died of perioperative and postoperative bleeding. This was 
particularly evident in the older patient population and in 
patients with extensive pleural or pericardial carcinoid plaques. 
The high incidence of perioperative and postoperative bleed- 
ing is thought to be multifactorial, including abnormal hepatic 
synthetic filnction with proionged prothrombin time, a reduced 
preoperative platelet count and a prolonged bleeding time. 
There appears to be no relation between hemorrhagic prob- 
lems and therapy with the somatostatin analog (29). Finally, 
advanced malignant carcinoid syndrome with carcinoid heart 
disease manifests with progressive pericardial and pleural 
carcinoid plaques. The patients in this series with extensive 
pericardial and pleural fibrosis were at increased risk of death 
at the time JE operation and had a poorer symptomatic 
outcome if they survived operation. 
Surgical reports have largely recommended tricuspid valve 
replacement and pulmonary valvectomy for the management 
of carcinoid heart disease (23). The initial recommendation for 
a mechanical tricuspid prosthesis was based on the assumed 
damage to the bioprosthetic valve from the vasoactive carci- 
noid tumor substances, but this has not been well established 
(25,27) and was postulated before the introduction of synthetic 
somatostatin, which may potentially protect prosthetic valve 
tissue from the adverse effects of serotonin and other vasoac- 
tive peptides. 
BioprcJlueuc valves are now favored over mechanical pros- 
theses for the tricuspid position at our institution because of a 
reduced risk of thrombosis and lack of need for systemic 
anticoagulation because patients with carcinoid syndrome are 
at higher risk of bleeding as a result of liver dysfunction. 
Hepatic dearterialization may be required for treatment of 
systemic carcinoid syndrome and further increases the risk of 
bleeding in patients receiving anticoagulation. Bioprosthetic 
tricuspid prostheses were placed in six patients, four of whom 
are still alive. No case of prosthetic valve failure caused by 
carcinoid involvement has been documented in the literature 
or From our series (mean follow-up, 28 months). A standard 
regimen for anticoagulation in our patients with carcinoid 
heart disease and mechanical tricuspid prostheses was insti- 
tuted, and the target international normalized ratio was 3.0 to 
4.5. Follow-up information regarding the number of bleeding 
episodes in patients receiving warfarin was not avaih.51~ 
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Patients with bioprosthetic valves were no! treated with an& 
coagulants. 
Operative survival was ass”ciated with higher voltage on the 
preoperative electrocardiogram (Fig. 3). Low voltage in carci- 
noid heart disease has been previously described (30) and may 
be related to more extensive endocardial and subendocardial 
involvement with carcinoid plaques, suggesting more advanced 
disease. Late survival was significantly associated with a lower 
preoperative somatostatin requirement and a lower preopera- 
tive 5-hydroxyindoleacetic acid level; these findings suggest 
that patients with less active OI extensive metastatic carcinoid 
disease have improved longevity postoperatively. 
The timing of cardiac operation for carcinoid heart disease 
remains difficult. No definitive guide!ines could be established 
from this review. It must be reemphasized rhat right ventricular 
size and function, right atrial size and left ventricular function 
did not correlate with nn~=+;*== VrW.yS.Icor late mortaiky. Our current 
practice includes functional evaluation by exercise testing to 
provide an objective assessment of the functiona: status and a 
guideline to the timing of cardiac surgery. Because of the very 
high perioperative mortality rate, patients with carcinoid heart 
i .sease currently are referred for cardiac operation only when 
they become markedly symptomatic. 
Limitations of the study. ‘l%i ;q the largest cardiac surgical 
series of patients with carcinoid heart disease studied to date. 
However, significant limitations exist in extrapolating these 
results to all patients with carcinoid heart disease. The heter- 
ogeneity of systemic and cardiac abnormalities and the small 
patient numbers reduce the significance of the data, with a 
resultant reduction in statistical power. The retrospective 
analysis, the use of a historical control group and incomplete 
preoperative data on all patients are also limitations. 
Conclusions. Because new therapies have improved sur- 
vival in patients with the malignant carcinoid syndrome, car- 
diac involvement has now become the major cause of morbid- 
ity and mortality. Cardiac operation is the only definitive 
treatment for patients with severe valvular involvement caused 
by carcinoid heart disease. Although cardiac operation for 
carcinoid heart disease is associated with a high perioperative 
mortality rate, and there is a significant late postoperative 
mortality rate in these patients, primarily from progression of 
the malignancy, marked symptomatic improvement occurs in 
most survivors after surgical intervention for carcinoid heart 
disease. It is therefore important to follow up the patients 
regularly and consider surgical intervention when cardiac 
symptoms become severe, albeit with a significant risk of 
perioperative mortality. 
On the basis of this early experience there is clearly a subset 
of patients with carcinoid heart disease who benefit signifi- 
cantly from valvular surgery. Continued refinement of sorgical 
technique and identification of preoperative determinants of 
outcome in addition to longer follow-up of bioprosthetic 
durability in the “carcinoid environment” are required to make 
specific treatment recommendations. 
1 be statistical asststance of Kent R. Bailey, PhD and thr secrrtxial assistance of 
Julie A. Klemmcnscn are greatly appreciated. 
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